Alloxan and Ninhydrin Inhibition of Hexokinase from Pancreatic Islets and Tumoural Insulin-Secreting Cells
- 1 March 1990
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 66 (3) , 157-162
- https://doi.org/10.1111/j.1600-0773.1990.tb00725.x
Abstract
Alloxan inhibited hexokinase activity in cytoplasmic fractions of transplantable radiation‐induced rat islet cell tumours, ob/ob mouse pancreatic islets, rat liver and rat kidney. Half maximal inhibitory concentrations of alloxan were greater than those previously found for half maximal inhibition of pancreatic islet or liver glucokinase. D‐glucose, preferentially the α‐anomer, and D‐mannose protected hexokinase activity against alloxan inhibition. 1,4‐Dithiothreitol completely protected against and partially reversed the alloxan inhibition of hexokinase. The ability of various dithiols to reverse the inhibition of hexokinase by alloxan was dependent on the spacing between the SH (thiol) groups. Only dithiols with intermediate spacing between the SH groups were effective. Dithiols with two vicinal SH groups such as 1,2‐dimercaptoethane and 2,3‐dimercaptopropanol (BAL) and dithiols with more widely spaced SH groups such as 1,5‐dimercaptopentane were ineffective. Thus a reaction of alloxan with two SH groups in the sugar binding site of the hexokinase with the formation of a disulfide bond may be involved in the reversible inhibition of the enzyme. Ninhydrin also inhibited hexokinase from all four tissues studied. The half maximal inhibitory concentrations of ninhydrin were lower than those of alloxan. Inhibition of hexokinase may be an important factor in the general cytotoxic action of ninhydrin. However, inhibition of pancreatic islet hexokinase is unlikely to be the initial event in the pancreatic B‐cell toxic action of alloxan, even if inhibition of hexokinase by high concentrations of alloxan may contribute to the B‐cell toxic action. Accordingly transplantable radiation‐induced rat islet cell tumours, in which glucose metabolism is primarily based on a high affinity glucose phosphorylating enzyme (hexokinase) activity, show resistance to alloxan toxicity. This contrasts with normal pancreatic B‐cells, which display high sensitivity to alloxan action and have a glucose metabolism critically dependent on the availability of low affinity glucose phosphorylating enzyme (glucokinase) activity.This publication has 16 references indexed in Scilit:
- Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibitionBritish Journal of Pharmacology, 1988
- Alloxan: history and mechanism of actionDiabetologia, 1988
- Signal recognition by pancreatic B-cellsBiochemical Pharmacology, 1988
- Effects of transplantation and resection of a radiation-induced rat insulinoma on glucose homeostasis and the endocrine pancreasBritish Journal of Cancer, 1987
- Defective regulation of glucokinase in rat pancreatic islet cell tumoursActa Endocrinologica, 1987
- Glucokinase in pancreatic B-cells and its inhibition by alloxanActa Endocrinologica, 1987
- Effects of cytotoxic drugs and inhibitors of insulin secretion on a serially transplantable rat insulinoma and cultured rat insulinoma cellsGeneral Pharmacology: The Vascular System, 1987
- Inhibition of rat liver glucokinase by alloxan and ninhydrin.CHEMICAL & PHARMACEUTICAL BULLETIN, 1985
- Action of Toxic Drugs on Islet CellsPublished by Elsevier ,1981
- A transplantable insulinoma in the rat.Proceedings of the National Academy of Sciences, 1977